Next Generation Sequencing (NGS) Market Poised to Hit $42.25 Billion by 2033: Key Drivers Behind the Surge - Latest Study by Grand View Research, Inc.

While next-generation sequencing (NGS) has become routine in academic settings, its use for patients with follicular lymphoma ...

Simple, Accurate, Affordable Solution for Pharmacogenomics Profiling to Identify Genetic Biomarkers Associated with Drug Response-- --Learn ...

Clear Labs announced its expanded automation platform and collaboration with Labcorp to develop streamlined, oncology-focused NGS workflows, marking its move beyond infectious disease sequencing and ...

Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the launch of oncoReveal® Lymphoid, a ...

OGT, using their specialised expertise in the development of superior hybridisation-based capture technology, ensures that ...

In the United States, healthcare professionals classify a disease as rare if it affects fewer than 200,000 individuals. As of August 7, 2024, the U.S. population consists of just under 336.9 million ...

The webinar series titled "The Basics of Next Generation Sequencing and its Application in Precision Oncology" aims to provide a comprehensive understanding of the fundamentals and practical ...

For managed care organizations and health systems, the recommendations strongly advocated highly selective use of NGS. Routine, nonselective NGS for all sarcoma patients is not justified. Instead, ...

This study demonstrates that NGS-MSI is noninferior to IHC-MMR and can identify MSI-H tumors that IHC-MMR is unable to detect and conversely IHC-MMR can identify MMRd tumors that NGS-MSI misses. This ...